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Abstract
Background: Widespread use of fluoroquinolones has resulted in emergence of Salmonella typhi
strains with decreased susceptibility to fluoroquinolones. These strains are identifiable by their
nalidixic acid-resistance. We studied the impact of infection with nalidixic acid-resistant S. typhi
(NARST) on clinical outcomes in patients with bacteriologically-confirmed typhoid fever.
Methods:  Clinical and laboratory features, fever clearance time and complications were
prospectively studied in patients with blood culture-proven typhoid fever, treated at a tertiary care
hospital in north India, during the period from November 2001 to October 2003. Susceptibility to
amoxycillin, co-trimoxazole, chloramphenicol, ciprofloxacin and ceftriaxone were tested by disc
diffusion method. Minimum inhibitory concentrations (MIC) of ciprofloxacin and ceftriaxone were
determined by E-test method.
Results: During a two-year period, 60 patients (age [mean ± SD]: 15 ± 9 years; males: 40 [67%])
were studied. All isolates were sensitive to ciprofloxacin and ceftriaxone by disc diffusion and MIC
breakpoints. However, 11 patients had clinical failure of fluoroquinolone therapy. Infections with
NARST isolates (47 [78%]) were significantly associated with longer duration of fever at
presentation (median [IQR] 10 [7-15] vs. 4 [3-6] days; P = 0.000), higher frequency of hepatomegaly
(57% vs. 15%; P = 0.021), higher levels of aspartate aminotransferase (121 [66–235] vs. 73 [44–119]
IU/L; P = 0.033), and increased MIC of ciprofloxacin (0.37 ± 0.21 vs. 0.17 ± 0.14 µg/mL; P = 0.005),
as compared to infections with nalidixic acid-susceptible isolates. All 11 patients with complications
were infected with NARST isolates. Total duration of illness was significantly longer in patients who
developed complications than in patients who did not (22 [14.8–32] vs. 12 [9.3–20.3] days; P =
0.011). Duration of prior antibiotic intake had a strong positive correlation with the duration of
fever at presentation (r = 0.61; P = 0.000) as well as the total duration of illness (r = 0.53; P = 0.000).
Conclusion: Typhoid fever caused by NARST infection is associated with poor clinical outcomes,
probably due to delay in initiating appropriate antibiotic therapy. Fluoroquinolone breakpoints for
S. typhi need to be redefined and fluoroquinolones should no longer be used as first-line therapy, if
the prevalence of NARST is high.
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Background
Typhoid fever is a common illness in developing coun-
tries like India [1] and is a potential threat to developed
nations, in an era of increasing air travel and global oper-
ations [2]. In the absence of appropriate chemotherapy,
typhoid fever was often a fatal illness and introduction of
effective antibiotic therapy in 1950s led to a sharp decline
in the rates of complications and mortality due to typhoid
fever [3]. However, in early 1990s multidrug-resistant
strains of Salmonella enterica serotype typhi (MDR-ST) that
were resistant to all the three first-line drugs then in use,
namely chloramphenicol, amoxycillin and co-trimoxa-
zole emerged, and sooner MDR-ST became endemic in
many areas of Asia, including India [4]. This change in
pattern of susceptibility was reflected even in places far
away, such as the United Kingdom [5] and the United
States of America [6]. Fluoroquinolones are very effective
against MDR-ST, achieving fever clearance in less than
four days with cure rates exceeding 96%, and are currently
the first-line drug for the treatment of typhoid fever [7].
However, towards the end of the last decade, it was
observed that fever took longer time than before to clear,
and at times surprisingly failed to respond to cipro-
floxacin therapy [8-10]. These isolates had comparatively
higher minimal inhibitory concentrations (MIC) of fluor-
oquinolones, although they were susceptible to fluoro-
quinolones by conventional disc diffusion testing and
recommended MIC breakpoints [8-10]. Nevertheless,
such strains of S. typhi are resistant to nalidixic acid and it
was noted that clinical response to fluoroquinolones in
patients infected with nalidixic acid-resistant S. typhi
(NARST) was inferior to the response in those infected
with nalidixic acid-sensitive S. typhi (NASST) strains [11].
However, it is not clear whether fluoroquinolones can still
be used as first-line drug for the treatment of typhoid
fever, and if used whether this has any adverse impact on
clinical outcomes other than treatment failure such as
development of complications and morbidity assessed in
terms of total duration of illness. In this scenario, the
present study was undertaken to evaluate the impact of




This study was conducted at the All India Institute of Med-
ical Sciences (A.I.I.M.S.) hospital, New Delhi, India. This
is a tertiary level medical centre located in north India,
serving predominantly to low and middle-income groups
of the population. All consecutive patients including chil-
dren with blood culture-proven typhoid fever, admitted
to the A.I.I.M.S. hospital during the period November
2001 through October 2003, and those treated as outpa-
tients during this period and were available for at least one
follow-up visit, were prospectively included in the study.
Patients were evaluated as per a pre-designed instrument,
regarding the demographic details, presenting symptoms,
physical and laboratory findings and complications.
Response to treatment was assessed in terms of fever clear-
ance time.
Microbiological methods
All isolates from blood culture were identified by standard
biochemical tests and confirmed by slide agglutination
test using specific Salmonella antiserum (Murex Diagnos-
tics Ltd., UK). Antibiotic susceptibility of the isolates was
determined by disc diffusion method using 5 µg disc of
ciprofloxacin and 30 µg disc of nalidixic acid (HiMedia
Laboratories Ltd., India), as per the National Committee
for Clinical Laboratory Standards (NCCLS) guidelines
and interpretive criteria [12]. The isolates were also tested
for susceptibility to chloramphenicol (30 µg), amoxycillin
(10 µg), co-trimoxazole (1.25/23.75 µg) and ceftriaxone
(30 µg) (HiMedia Laboratories Ltd., India) by disc diffu-
sion method [12]. Minimum inhibitory concentrations
(MIC) of ciprofloxacin and ceftriaxone were determined
by the E-test method, using commercially available strips
(AB Biodisk, Sweden), as per manufacturer's
specifications.
Definitions
A case of typhoid fever was defined as one that presented
with a febrile illness, whose blood culture yielded S. typhi.
Susceptibility break points to various antibiotics tested,
were taken as per NCCLS definitions [12]. Anaemia was
defined as haemoglobin less than 100 g/L. Leucopenia
was defined as total leucocyte count less than 4 × 109 cells/
L and thrombocytopenia as platelet count less than 100 ×
109platelets/L. Leucocytosis was defined as total leucocyte
count more than 11 × 109 cells/L. Liver enzymes were con-
sidered as elevated if the levels were more than two times
the upper limit of normal (cut-off of 100 IU/L for both
alanine aminotransferase and aspartate aminotransferase;
560 IU/L for alkaline phosphatase). Fever clearance time
was defined as the time from the start of appropriate anti-
biotic therapy to the first instance, when oral temperature
fell to 37.5°C and remained below that level continu-
ously for 48 hours. Clinical failure of fluoroquinolone
therapy was defined as continuing fever, even after five
days of continuous treatment with a fluoroquinolone.
Treatment of typhoid fever
The choice of antibiotic therapy was at the discretion of
the treating physician. The practice in general, was to pre-
scribe oral ciprofloxacin (adults: 500 mg b.i.d.; children:
15 mg/kg/day) or ofloxacin (adults: 400 mg b.i.d.; chil-
dren: 15 mg/kg/day) or cefixime (20 mg/kg/day) for out-
patient treatment and to admit the patient for in-patient
care, if felt by the treating physician to be not respondingBMC Infectious Diseases 2005, 5:37 http://www.biomedcentral.com/1471-2334/5/37
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to therapy or acutely ill. Hospitalised patients received
parenteral antibiotic therapy, either ceftriaxone (adults: 2
g b.i.d.; children: 75 mg/kg/day) or a fluoroquinolone or
a combination regimen, as decided by the treating
physician.
Statistical analysis
All statistical analyses were done using a software package
(SPSS for Windows, Version 10.0.1, SPSS Inc., Chicago,
IL). Continuous variables are presented as mean ± stand-
ard deviation (SD) or as median with interquartile range
(IQR). Categorical variables are expressed as proportions.
Independent sample t test or Mann-Whitney U test as
appropriate was applied for the comparison of continu-
ous variables between two groups and categorical varia-
bles were compared by chi-squared test or Fisher's exact
test. Correlation between two continuous variables such
as total duration of illness and duration of prior antibiotic
intake was tested by Pearson's product moment correla-
tion. Comparison of continuous variables between more
than two groups was done by Kruskal-Wallis test. P-value
less than 0.05 was considered statistically significant. All
tests were two-sided.
Results
Over a period of two years, 60 patients (hospitalised: 49,
outpatients: 11) with blood culture-proven typhoid fever
were included in the study. In patients who had relapse,
only the first episode was considered in the analysis. Mean
age of the patients was 15 ± 9 years (range: 6 months-39
years). Overall, males were predominantly affected (40
patients, 67%). The predilection for male gender was seen
in all age groups (in decades), except in infants and pre-
school children (0–5 years) where the gender distribution
was nearly equal (n = 13; 7 males). The frequency of vari-
ous symptoms and physical findings at presentation is
shown in Table 1.
All 60 isolates were sensitive to ciprofloxacin by disc dif-
fusion testing and the MIC values of ciprofloxacin for all
the isolates were within the susceptible range (0.016–1
µg/mL) as per current NCCLS definitions (susceptible if,
MIC ≤  1 µg/mL). Forty seven isolates (78%) were resistant
to nalidixic acid (NARST) and the frequency of resistance
to other antibiotics namely, chloramphenicol, amoxycil-
lin and co-trimoxazole was 26 (43%), 28 (47%) and 30
(50%) respectively. About a third of isolates were MDR-ST
(22 isolates, 37%) and no isolate was resistant to ceftriax-
Table 1: Clinical features at presentation, in a study of 60 patients with blood culture-proven typhoid fever
Characteristic Frequency, overall (n = 60) NARST (n = 47) NASST (n = 13) MDR-ST (n = 22) NonMDR-ST (n = 38)
Age, years * 15 ± 9 13 ± 9 † 23 ± 8 † 14 ± 9 16 ± 10
Gender (male/female) 40/20 32/15 8/5 15/7 25/13
Fever, days ‡ 8 (4.8–14) 10 (7–15) † 4 (3–6) † 9 (7–14.3) 7 (3.8–14)
Chills 39 (65) 30 (64) 9 (69) 15 (68) 24 (63)
Anorexia 58 (97) 46 (98) 12 (92) 22 (100) 36 (95)
Abdominal pain 23 (38) 18 (38) 5 (38) 10 (45) 13 (34)
Vomiting 33 (55) 27 (57) 6 (46) 14 (64) 19 (50)
Diarrhoea 27 (45) 22 (47) 5 (38) 11 (50) 16 (42)
Constipation 7 (12) 6 (13) 1 (8) 2 (9) 5 (13)
Intestinal bleeding 1 (2) 1 (2) -- -- 1 (3)
Headache 24 (40) 19 (40) 5 (38) 6 (27) 18 (47)
Altered sensorium 3 (5) 3 (6) -- 2 (9) 1 (3)
Cough 21 (35) 18 (38) 3 (23) 10 (45) 11 (29)
Relative bradycardia 6 (10) 4 (9) 2 (15) 1 (5) 5 (13)
Jaundice 3 (5) 3 (6) -- -- 3 (8)
Hepatomegaly § 29 (49) 27 (57) || 2 (15) || 11 (50) 18 (47)
Splenomegaly § 30 (51) 25 (53) 5 (38) 14 (64) 16 (42)
NARST = nalidixic acid-resistant Salmonella typhi
NASST = nalidixic acid-sensitive Salmonella typhi
MDR-ST = multidrug-resistant Salmonella typhi
-- no patients in this category
All data presented as number (%) of patients, except when indicated
* data presented as mean ± SD
† P-value < 0.05 for NARST vs. NASST; compared by independent t test or Mann-Whitney U test
‡ duration of fever at presentation; presented as median (IQR)
§ one patient with underlying chronic myeloid leukaemia was not included
|| P-value < 0.05 for NARST vs. NASST; compared by Fisher's exact testBMC Infectious Diseases 2005, 5:37 http://www.biomedcentral.com/1471-2334/5/37
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one (MIC range: 0.016–0.064 µg/mL; susceptible if, MIC
≤  8 µg/mL).
When compared with NASST, the mean MIC of cipro-
floxacin was significantly higher for NARST isolates (Table
2; P = 0.005). However, the distribution of MIC values of
ciprofloxacin around the mean, in the two groups was
wide and there was considerable overlap. When dichot-
omised using the median value of MIC (0.25 µg/mL), iso-
lates with MIC values above the median were significantly
more likely to be resistant to nalidixic acid (NARST) than
were isolates with MIC values below the median (P =
0.013; Figure 1). As a surrogate marker, nalidixic acid-
resistance was 82% sensitive and 100% specific for identi-
fying isolates with MIC of ciprofloxacin ≥  0.125 µg/mL.
About half of the patients (47%) presented in the first
week of illness. The duration of fever at presentation was
significantly longer in patients with NARST isolates (Table
1; P = 0.000) as was the total duration of illness (Table 2;
P = 0.000), than in patients with NASST isolates. The fre-
quency of various laboratory abnormalities, according to
the susceptibility of the isolate is shown in Table 3. Anti-
biotic susceptibility pattern had no significant association
with any of the physical findings except for hepatomegaly
(P = 0.021), which was more frequent in patients with
NARST isolates (Table 1). Elevation of hepatic enzymes
was a common feature (27 patients, 45%) and in four
patients the elevation was marked (> 5 times the upper
limit of normal), among which three patients had con-
comitant hyperbilirubinaemia. Patients with NARST iso-
lates had significantly higher levels of aspartate
aminotransferase than patients with NASST isolates (121
[66–235] vs. 73 [44–119] IU/L; P = 0.033). Though the
mean levels of alanine aminotransferase and alkaline
phosphatase were higher in patients with NARST isolates,
these differences were not statistically significant (data not
shown).
Twenty six patients (43%) had received prior oral antibi-
otic therapy as outpatients, for a variable duration (2–17
days) before presentation: of which 11 patients (42%)
had received fluoroquinolones for at least five days dura-
tion and thus were deemed to have clinical failure of fluo-
roquinolone therapy (others: cefixime – 7 patients [2–15
days]; ciprofloxacin – 4 patients [2–4 days]; amoxycillin –
3 patients [2–4 days]; azithromycin – 1 patient [2 days]).
Among these 11 patients, three patients remained febrile
even after 10 days of fluoroquinolone therapy. However,
all the 11 isolates from patients with fluoroquinolone-
failure were sensitive to ciprofloxacin in vitro, according to
current NCCLS breakpoints (mean MIC: 0.34 ± 0.11 µg/
mL; range: 0.125–0.5 µg/mL). Of the 11 instances of clin-
ical failure of fluoroquinolone, in 10 patients the isolates
were NARST.
Fever clearance times were assessable in 51 patients (5
patients were lost to follow-up and in the other 4 patients
defervescence was confounded by co-existing conditions).
The initial antibiotic regimens were: ceftriaxone alone (35
patients) or in combination with another antibiotic (6
patients) and ofloxacin alone (7 patients) or in combina-
tion (3 patients) (Figure 2). Overall, the mean fever
clearance time was 5 ± 3.5 days (range: 1–18.5 days).
Clearance of fever took seven days or more in 10 patients
(20%). Fever clearance time had no significant association
with age, gender, antibiotic susceptibility pattern, MIC of
ciprofloxacin, MIC of ceftriaxone, or the antibiotic regi-
men used for treatment. Overall, 11 patients (18%) devel-
oped complications, which included encephalopathy (4
patients), meningitis (1 patient), hepatitis characterised
by marked elevation of transaminases (4 patients), myo-
carditis and massive lower gastrointestinal bleeding (1
Table 2: Antibiotic susceptibility and clinical outcomes in a study of 60 patients with blood culture-proven typhoid fever
Variable All patients (n = 60) NARST (n = 47) NASST (n = 13) MDR-ST (n = 22) NonMDR-ST (n = 38)
MIC ciprofloxacin, µg/mL 0.33 ± 0.21 0.37 ± 0.21* 0.17 ± 0.14* 0.37 ± 0.26 0.30 ± 0.18
MIC ceftriaxone, µg/mL 0.036 ± 0.016 0.038 ± 0.018 0.031 ± 0.01 0.033 ± 0.017 0.039 ± 0.016
Fever clearance time, days 5.1 ± 3.5 5.5 ± 3.8 3.7 ± 1.3 4.9 ± 2.7 5.3 ± 3.9
Total duration of illness, days 14.3(9.8–21) 16.3(11.4–24)* 9.6(6.8–10)* 14.5(9.3–21.4) 14.3(9.9–22)
Complications † 11 (18) 11 (23) -- 2 (9) 9 (24)
NARST = nalidixic acid-resistant Salmonella typhi
NASST = nalidixic acid-sensitive Salmonella typhi
MDR-ST = multidrug-resistant Salmonella typhi
MIC = minimum inhibitory concentration
-- no patients in this category
* P-value < 0.05 for NARST vs. NASST; compared by independent t test or Mann-Whitney U test
† includes encephalopathy, hepatitis, lower gastrointestinal bleeding, meningitis and myocarditis. Presented as number (%) of patients; all other data 
given as mean ± SD or median (IQR)BMC Infectious Diseases 2005, 5:37 http://www.biomedcentral.com/1471-2334/5/37
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patient each). All 11 patients who developed complica-
tions had NARST isolates. However, this apparent differ-
ence between NARST and NASST in the development of
complications was not statistically significant (P = 0.1).
Total duration of illness was significantly longer in
patients who developed complications than in patients
who did not (22 [14.8–32] vs. 12 [9.3–20.3] days; P =
0.011). This difference became non-significant (P =
0.087) after adjusting for the duration of prior antibiotic
intake, suggesting that the difference in the duration of
prior antibiotic intake contributed to the apparent differ-
ence in the total duration of illness. The duration of fever
at presentation was significantly longer in patients who
had received prior antibiotic therapy than in patients who
had not (12 [7–22.5] vs. 7 [3-10]; P = 0.009) and there
was a strong positive correlation between duration of
prior antibiotic intake and duration of fever at presenta-
tion (r = 0.61; P = 0.000) as well as total duration of illness
(r = 0.53; P = 0.000). When patients with NARST isolates
were subdivided on the basis of presence or absence of
complications, it became apparent that even among
patients with NARST isolates, the duration of fever at pres-
entation was comparatively longer in those with compli-
cations than those who had NARST isolates but no
complications, exhibiting a linear trend (Figure 3; P =
0.001). No significant differences were observed when
patients with MDR-ST isolates were compared with the
rest, with respect to any of the parameters studied, includ-
ing rate of complications and total duration of illness
(Tables 1, 2 and 3).
Discussion
The present study brings out the high frequency of nalid-
ixic acid-resistance among S. typhi isolates from New
Delhi, India. Moreover, this study reconfirms the occur-
Histogram depicting the distribution of minimum inhibitory concentration (MIC) of ciprofloxacin of 60 Salmonella typhi isolates  and the proportion of nalidixic acid-resistant (NARST) as well as nalidixic acid-susceptible (NASST) isolates in each column Figure 1
Histogram depicting the distribution of minimum inhibitory concentration (MIC) of ciprofloxacin of 60 Salmonella typhi isolates 
and the proportion of nalidixic acid-resistant (NARST) as well as nalidixic acid-susceptible (NASST) isolates in each columnBMC Infectious Diseases 2005, 5:37 http://www.biomedcentral.com/1471-2334/5/37
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rence of ciprofloxacin-susceptible but nalidixic acid-resist-
ant S. typhi isolates and their relation to clinical failure of
fluoroquinolone therapy. The frequency of nalidixic acid-
resistance as found in the present study (78%) is high in
comparison with earlier studies from India, in which it
was in the range of 60–67% [13,14]. However, it should
be highlighted that these studies were temporally sepa-
rated, hindering direct comparison between them. Being a
hospital-based study, NARST strains might have been
inadvertently overrepresented in the study population,
since patients infected with NASST are more likely to be
successfully treated in the community setting with fluoro-
quinolones. A community-based study is needed to esti-
mate the actual proportion of infections caused by
NARST. An earlier community-based prospective study
conducted in New Delhi had found an alarmingly high
rate of ciprofloxacin failure (9 out of 63 patients, 14%) as
early as 1995–96 [1]. In light of the consistent increase in
the proportion of NARST isolates over the last decade, as
suggested by data collected at our Institute [15], the high
frequency of NARST strains as found in the present study
seems to be a true phenomenon rather than due to selec-
tion bias. As documented in an earlier study conducted in
south India [16], this increase in the frequency of NARST
strains is associated with a consistent increase in the MIC
levels of ciprofloxacin for S. typhi isolates [15].
Interesting is the fact that as per the current NCCLS break-
points, these NARST isolates with higher MIC of cipro-
floxacin would still be classified as being ciprofloxacin-
susceptible. Notwithstanding, this subtle increase in the
MIC of ciprofloxacin had an adverse impact on the clini-
cal response to fluoroquinolone therapy: in the present
study, all patients with clinical failure of fluoroquinolone
therapy had isolates with MIC of ciprofloxacin ≤  1 µg/mL.
Hence, it is increasingly being felt that the common fluo-
roquinolone breakpoints for Enterobacteriaceae as set by
the NCCLS, are to be reevaluated in the case of Salmonella
species [13,17,18]. Currently, the NCCLS advises that test-
ing of extraintestinal Salmonella isolates for nalidixic acid-
resistance may be considered and that fluoroquinolone-
susceptible strains of Salmonella that test resistant to nali-
dixic acid may be associated with clinical failure or
delayed response in fluoroquinolone-treated patients
with extraintestinal salmonellosis [19]. In consonance
with earlier studies [13,20], the sensitivity of nalidixic
acid-resistance as a surrogate marker for identifying iso-
lates with increased levels of MIC of ciprofloxacin was
found to be good in the present study. Thus, testing for
nalidixic acid-resistance could be useful as a screening test
for further determination of MIC levels of ciprofloxacin.
Since fluoroquinolones exhibit concentration-dependent
killing, using higher doses of ciprofloxacin (750 mg b.i.d.)
might compensate for this reduced susceptibility [7,21].
Area under the curve (AUC) for serum concentrations
attained with this dose is 19.2 ± 1.1 µg.h/mL [22]. This
extrapolates to an AUC/MIC ratio of about 77 in the case
of half of the isolates encountered in the present study,
which is well below the cut-off of > 250 that is required for
rapid bactericidal action [23]. Thus using higher doses of
ciprofloxacin is also likely to prove ineffective in this
population.
Table 3: Haematological and biochemical findings in a study of 60 patients with blood culture-proven typhoid fever
Variable Frequency, overall (n = 60) NARST (n = 47) NASST (n = 13) MDR-ST (n = 22) NonMDR-ST (n = 38)
Anaemia * 19 (32) 15 (32) 4 (31) 6 (27) 13 (34)
Leucopenia * 10 (17) 8 (17) 2 (15) 4 (18) 6 (16)
Leucocytosis * 6 (10) 5 (11) 1 (8) 2 (9) 4 (11)
Thrombocytopenia * 8 (13) 6 (13) 2 (15) 3 (14) 5 (13)
AST > 2 × ULN 27 (45) 23 (49) 4 (31) 9 (41) 18 (47)
AST > 5 × ULN 8 (13) 8 (17) -- 3 (14) 5 (13)
ALT > 2 × ULN 18 (30) 16 (34) 2 (15) 6 (27) 12 (32)
ALT > 5 × ULN 4 (7) 4 (9) -- 1 (5) 3 (8)
NARST = nalidixic acid-resistant Salmonella typhi
NASST = nalidixic acid-sensitive Salmonella typhi
MDR-ST = multidrug-resistant Salmonella typhi
AST = alanine aminotransferase
ALT = aspartate aminotransferase
ULN = upper limit of normal
MIC = minimum inhibitory concentration
-- no patients in this category
* defined by cut-off values as given in the text
All data presented as number (%) of patientsBMC Infectious Diseases 2005, 5:37 http://www.biomedcentral.com/1471-2334/5/37
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Antibiotic therapy and fever clearance time in a study of 60 patients with blood culture-proven typhoid fever Figure 2
Antibiotic therapy and fever clearance time in a study of 60 patients with blood culture-proven typhoid fever. 
Numbers in parentheses represent the number of patients * 26 patients had received some antibiotic for variable duration 
before presentation, of which 11 patients remained febrile, even after taking fluoroquinolones for ≥  5 days † fever clearance 
time, presented as mean ± SD (days) ‡ other antibiotics given in combination with ceftriaxone were: ofloxacin (3 patients), ami-
kacin (2 patients) and azithromycin (1 patient) § miscellaneous regimens were: cefixime + amoxycillin (1 patient), ceftriaxone + 
ofloxacin + metronidazole (1 patient) and ceftriaxone + ciprofloxacin + gentamicin (1 patient) || antibiotics added were: ami-
kacin (3 patients) and ofloxacin (2 patients) ¶ switched over to azithromycin (1 patient) and ofloxacin (1 patient)BMC Infectious Diseases 2005, 5:37 http://www.biomedcentral.com/1471-2334/5/37
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Higher frequency of hepatomegaly with greater elevation
of hepatic enzymes and a trend for increased incidence of
complications in patients with NARST isolates, all suggest
that NARST is associated with severe clinical illness.
Though the present study did not find a statistically signif-
icant association between NARST and the rate of compli-
cations, current findings strongly suggest that prior intake
of antibiotics not capable of achieving fever clearance is
associated with the development of complications. Thus it
is reasonable to presume that the use of ciprofloxacin in
populations where NARST is widely prevalent would
delay the initiation of appropriate antibiotic therapy and
thereby would lead to an excess of complications. The
current observations are consistent with this hypothesis,
though not confirmatory.
Earlier studies had reported that infection caused by
MDR-ST was associated with more severe illness than
non-MDR-ST infection [24,25]. Noteworthy is the fact
that in both these studies antibiotic used as first-line ther-
apy was ampicillin/amoxycillin or chloramphenicol, to
which MDR-ST is inherently resistant. Contrary to this,
the present study and another study [26] using cipro-
floxacin as first-line therapy found no significant differ-
ences between MDR-ST and non-MDR-ST infections. This
analogy offers ancillary evidence in support of the
hypothesis that using fluoroquinolones as first-line ther-
apy in settings where NARST is prevalent, would result in
poor outcomes. The other possibility is that development
of drug resistance and virulence of the organism might be
genetically linked. Blood bacterial counts were reported to
be substantially higher in infections caused by MDR-ST
than in infections caused by drug-susceptible S. typhi [27].
A similar phenomenon is possible in the case of NARST
also, accounting for poor outcomes. But the present study
was not aimed at evaluating this possibility and this mer-
its further study.
Duration of fever at presentation, according to nalidixic acid-susceptibility status and presence of complications Figure 3
Duration of fever at presentation, according to nalidixic acid-susceptibility status and presence of complica-
tions. Data presented as mean ± SE NASST = nalidixic acid-sensitive Salmonella typhi NARST = nalidixic acid-resistant Salmo-
nella typhiBMC Infectious Diseases 2005, 5:37 http://www.biomedcentral.com/1471-2334/5/37
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Conclusion
In this population, nalidixic acid-resistance is very com-
mon among isolates of S. typhi and is associated with
reduced susceptibility to fluoroquinolones in vitro. Clini-
cally this translates into frequent failure of fluoroqui-
nolone therapy. However, this is not reflected in current
NCCLS breakpoints and hence the fluoroquinolone
breakpoints need to be redefined for S. typhi. Moreover,
use of fluoroquinolones as first-line therapy for typhoid
fever delays initiation of appropriate antibiotic in this set-
ting and is likely to result in poor outcomes. For these rea-
sons, fluoroquinolones should no longer be used as the
first-line therapy, in populations where nalidixic acid-
resistance is common among isolates of S. typhi.
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